Comparative Pharmacology
Head-to-head clinical analysis: PHENAPHEN W CODEINE NO 4 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENAPHEN W CODEINE NO 4 versus QOLIANA.
PHENAPHEN W/ CODEINE NO. 4 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenaphen w/ Codeine No. 4 contains acetaminophen and codeine. Acetaminophen inhibits prostaglandin synthesis in the CNS, reducing pain and fever. Codeine, an opioid prodrug, is converted to morphine via CYP2D6 and binds to mu-opioid receptors, inhibiting ascending pain pathways.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
1-2 tablets (300-600 mg acetaminophen / 30-60 mg codeine phosphate) orally every 4 hours as needed for pain; maximum 12 tablets per day.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
Codeine: 2.5-3.5 h; morphine: 2-4 h; clinically, analgesia correlates with morphine levels
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal: 90-100% as codeine and metabolites (codeine: 5-15%, morphine: 10%, norcodeine: 10%, morphine-3-glucuronide: 50%, morphine-6-glucuronide: <5%); biliary/fecal: minimal (<5%)
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist